Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria

Similar documents
COMORBIDITY OF IRRITABLE BOWEL SYNDROME, PANIC DISORDER, AND AGORAPHOBIA IN THE GENERAL POPULATION IN JAPAN

Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population

Prevalence and management of abdominal cramping and pain: a multinational survey

Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey

Masanori Kosako 1*, Hiraku Akiho 2, Hiroto Miwa 3, Motoyori Kanazawa 4 and Shin Fukudo 4

Alternating bowel pattern: what do people mean?

ALMIRALL AND IRONWOOD ANNOUNCE POSITIVE RESULTS FROM A PHASE 3 TRIAL WITH LINACLOTIDE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

At the outset, we want to clear up some terminology issues. IBS is COPYRIGHTED MATERIAL. What Is IBS?

Epidemiology and Impact of IBS

Emerging Treatments for IBS-C and Clinical Trial Endpoints

Gastrointestinal Society 2016 SURVEY RESULTS

IBS: overview and assessment of pain outcomes and implications for inclusion criteria

JNM Journal of Neurogastroenterology and Motility

Accepted Article. Irritable bowel syndrome (IBS) subtypes: Nothing. Fermín Mearin Manrique. DOI: /reed /2016 Link: PDF

IBS - Definition. Chronic functional disorder of GI generally characterized by:

Uncomplicated diverticular disease is not a common cause of colonic symptoms

Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1-year follow-up study (RITMO study)

David Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:

J Neurogastroenterol Motil, Vol. 16 No. 2 April, 2010 DOI: /jnm Journal of Neurogastroenterology and Motility

AN EXPERT SYSTEM FOR THE DIAGNOSIS OF IRRITABLE BOWEL SYNDROME

IBS IBS. irritable bowel syndrome IBS IBS. in situ. E -hydroxy-l-tryptophan. -dihydroxy- -hexadien IBS IBS IBS IBS.

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011

Diagnosis and Management of Irritable Bowel Syndrome (IBS) For the Primary Care Provider

A Prospective Assessment of Bowel Habit in Irritable Bowel Syndrome in Women: Defining an Alternator

Validated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population

... SELECTED ABSTRACTS...

Prevalence of Irritable Bowel Syndrome among Medical Students and Interns in Jeddah, Saudi Arabia

Applying Case Definition Criteria to Irritable Bowel Syndrome

Why does my stomach hurt? Exploring irritable bowel syndrome

Adequate Relief in a Treatment Trial With IBS Patients: A Prospective Assessment

Disclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome

Digestion. Text. What You Don t Know Can Hurt You!

Irritable bowel syndrome (IBS) is a ... PRESENTATION... Defining and Diagnosing Irritable Bowel Syndrome

THREE BASIC APPROACHES TO MEASURING THE HRQOL IMPACT OF MEDICAL CONDITIONS

The Risk Factors and Quality of Life in Patients with Overlapping Functional Dyspepsia or Peptic Ulcer Disease with Gastroesophageal Reflux Disease

Irritable Bowel Syndrome and Chronic Constipation. Treatment of IBS. Susan Lucak, M.D. Columbia University Medical Center

Jelly like mucus after diarrhea

Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea

WOMEN WITH IRRITABLE BOWEL SYNDROME ACCORDING TO ROME II CRITERIA IN JORDAN

What should be the primary end point in irritable bowel syndrome?

ANSlmicett. Research Paper. Irritable Bowel Syndrome in Iranian Young Adults: A Survey among Medical Students

William D. Chey, MD, FACG. Page 1 of ACG Midwest Regional Postgraduate Course Copyright 2016 American College of Gastroenterology

Sohair A Hagag *1, Shereen Eassa 1 and Mahmoud Abdou Aashour 2

Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary

SUPPLEMENTARY INFORMATION Associated with

2. Have your symptoms affected your ability to carry out your daily activities? YES NO


FUNCTIONAL GI DISORDERS ORIGINAL CONTRIBUTIONS

Irritable Bowel Syndrome: Toward an Understanding of Severity

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 June 2011

The burden and management of patients with IBS: results from a survey in Spanish gastroenterologists

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study

Article: Min, T and Ford, AC (2016) Efficacy of mesalazine in IBS. Gut, 65 (1). pp ISSN

Factors Influencing Satisfaction with Life in Female Nursing College Students with Irritable Bowel Syndrome

What is Irritable Bowel Syndrome (IBS)?

Functional Foods in Health and Disease 2018; 8(9): Page 462 of 471

Diagnostic value of the Manning criteria in irritable bowel syndrome

Presenter. Irritable Bowel Syndrome. Objectives. Introduction. Rome Criteria. Irritable Bowel Syndrome 2/28/2018

FUNCTIONAL DISORDERS TREATMENT ADVANCES. Dr. Adriana Lazarescu MD FRCPC Director GI Motility Lab, Edmonton Associate Professor University of Alberta

IBS. Patient INFO. A Guide to Irritable Bowel Syndrome

Please complete this voiding diary and questionnaire. Bring both of them with you to your next appointment with your provider.

Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults

Vicente Garrigues, Consuelo Gálvez, Vicente Ortiz, Marta Ponce, Pilar Nos, and Julio Ponce

William D Chey, 1 Anthony J Lembo, 2 James A Phillips, 3 David P Rosenbaum 4

Diarrhea may be: Acute (short-term, usually lasting several days), which is usually related to bacterial or viral infections.

Post-Infectious Irritable Bowel Syndrome. John K. Marshall MD Division of Gastroenterology McMaster University

Copyright The Food Intolerance Testing Group. All rights reserved. No part of this publication may be

BioPsychoSocial Medicine

Silver Child Development Center New Patient Questionnaire. Relation (circle) Biological Mother Stepmother Adoptive Mother

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation

T he irritable bowel syndrome (IBS) is a symptom complex

Bloating, Flatulence, and

Copyright note. Wensaas 1

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case control study

Patient Satisfaction with IBS Symptom Relief Using a Novel Peppermint Oil Delivery System in a Randomized Clinical Trial and in the General Population

1.* Have you been bothered by PAIN OR DISCOMFORT IN YOUR UPPER ABDOMEN OR THE PIT OF YOUR STOMACH during the past week?

Psychometric Characteristics of the Persian Version of the Irritable Bowel Syndrome Quality of Life Questionnaire (P-IBS-QOL)

Emotional Relationships Social Life Sexually Recreation

Follow-up of Celiac Disease

MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-

IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

*521634* Sleep History Questionnaire. Name of primary care doctor:

IBS is associated with an increased incidence of psychological

MOVICOL Launched in Japan -The First Polyethylene Glycol Preparation for Chronic Constipation in Japan-

Irritable Bowel Syndrome and Mood Disorders Pedro Ramos, University of Louisville, Louisville, KY

Epidemiology of Functional Diarrhea and Comparison with Diarrhea-Predominant Irritable Bowel Syndrome: A Population-Based Survey in China

Bend Surgical Associates. Michael J. Mastrangelo, MD, FACS. Medication Name Dosage Frequency Medication Name Dosage Frequency

High Prevalence of Nausea in Children With Pain-Associated Functional Gastrointestinal Disorders: Are Rome Criteria Applicable?

Evaluation of Efficacy Variables in Clinical Study of Irritable Bowel Syndrome with Diarrhea

Icd 10 code for vaginal itching and burning

Symptom Review (page 1) Name Date

Buy full version here - for $7.00

Validation of a Four-Graded Scale for Severity of Heartburn in Patients with Symptoms of Gastroesophageal Reflux Disease

Studies have shown that familial aggregation is of

The Food Intolerance Institute of Australia

Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials

Modesto Gastroenterology Medical Corporation

Diagnosing and Managing IBS in IBD Patients. September 2012

Transcription:

ORIGINAL RESEARCH Prevalence of irritable bowel syndrome in Japan: Internet survey using Rome III criteria Hiroto Miwa Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Objectives: We conducted a large-scale Internet survey of 10,000 subjects across Japan to determine irritable bowel syndrome (IBS) prevalence. (J-ROAD: Japanese research of abdominal symptoms for IBS) Methods: An equal number of male and female subjects, aged at least 20 years, were surveyed by questionnaire. The prevalence of IBS and its subtypes were determined using Rome III criteria, and the results were analyzed for gender- and age-related differences. IBS prevalence was also determined using Rome II criteria for comparison with Rome III criteria results. Results: IBS prevalence based on Rome III criteria was 13.1%. IBS with diarrhea (IBS-D) subtype accounted for 29% of these cases, IBS with constipation (IBS-C) subtype 24% of cases, and mixed IBS (IBS-M) subtype 47% of cases. IBS-D was more common in men, while IBS-C predominated in women. IBS was most frequently associated with the 20 29 year age bracket, with prevalence decreasing with age. IBS prevalence based on Rome II criteria was 9.8%. Conclusion: IBS prevalence based on Rome III criteria was 13.1%. On the other hand, IBS prevalence based on Rome II criteria was 9.8%. Diagnosis based on these updated criteria may uncover more IBS cases than Rome II criteria. Keywords: irritable bowel syndrome, Rome, epidemiology, prevalence Correspondence: Hiroto Miwa Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan Tel +81 79 845 6665 Fax +81 79 845 6661 Email miwahgi@hyo-med.ac.jp Introduction Irritable bowel syndrome (IBS) is one of the functional gastrointestinal disorders (FGIDs) characterized by gastrointestinal symptoms such as abdominal pain or discomfort, and alteration of bowel habits, despite the absence of organic disease (Drossman et al 1994, 1997). IBS is a digestive disorder with high prevalence. Prevalence ranges from 10 to 15% of the general population in major civilized countries, with incidence of 1 to 2% annually (Talley 1999). IBS prevalence varies greatly according to gender. In the West, 2 to 4 times more women exhibit IBS than men (Chang et al 2002). Women have also been shown to be more prone to constipation-predominant IBS than men (Kang 2005). The syndrome generally develops in the late teens to 20s, with onset decreasing with age (Saito et al 2002). In a small-scale epidemiological study conducted in Japan, IBS prevalence based on Rome II criteria was 14.2% (12.9% male, 15.5% female; N = 417) (Kanazawa et al 2004). The largest-scale epidemiological study was conducted by Kumano and his colleagues (2004) and according to their study report, the IBS prevalence based on Rome II criteria was 6.1% (4.5% male, 7.8% female; N = 4,000). Compared with major western countries, the gender difference was low, while the prevalence was similar. IBS is conventionally thought of as a neurotic disease. The establishment of the FGIDs concept in recent years has led to a growing need for the development of IBS diagnostic criteria. The Manning criteria (Manning et al 1978) were developed in 1978, followed by the Rome I criteria (Thompson et al 1992) in 1992. The latter was developed as a global diagnostic standard and underwent revision Patient Preference and Adherence 2008:2 143 147 143 2008 Miwa, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

Miwa in 1999 due to its complex and difficult application. The resulting Rome II criteria (Thompson et al 1999) were simple and practical, enabling their use in a large number of studies and clinical trials. Rome III criteria (Longstreth et al 2006) were announced in May 2006 and changed the required duration of symptoms from the last 12 months to the past six months. These criteria also classify the disease among four categories: IBS with diarrhea (IBS- D), IBS with constipation (IBS-C), mixed IBS (IBS-M), unsubtyped IBS (IBS-U). Here, we set out to conduct the first large-scale IBS epidemiological study in Japan in accordance with Rome III criteria. The objectives of this study were (1) to determine IBS prevalence, subtype classification, gender ratio, and age prevalence, as well as (2) to compare IBS prevalence estimates from the same study population based on Rome II criteria and Rome III criteria. Materials and methods Subjects With the cooperation of Social Survey Research Information Co., Ltd. (Shinjuku, Tokyo), 10,000 general consumers from 47 prefectures in Japan were selected as subjects using the stratified random sampling method. All subjects were at least 20 years of age and were stratified into five age categories (20s, 30s, 40s, 50s, 60 and above). Subjects consisted of 5,000 males and 5,000 females, with each age group consisting of 1,000 subjects. They were surveyed using the Internet beginning from May 23, 2006 until May 30, 2006. Questionnaires Descriptions of symptoms in the questionnaire were prepared in accordance with IBS items in Rome III criteria due to the absence of a validated Japanese questionnaire. All questions were simplified to enable the participants to understand the meaning of questions easily (Figure 1). Diagnostic criteria Subjects were categorized as having IBS based on Rome III and Rome II criteria (Figure 2). To meet the IBS classification according to Rome II or III criteria, subjects must have had bowel habits that were consistent with each respective criterion, without meeting any exclusion criteria. Rome III subtype classification was performed as follows. Subjects affected mainly by loose bowels/diarrhea were classified into IBS-D. Those that were mainly affected by constipation were classified into IBS-C, and those with both were considered to be IBS-M. Results The total IBS prevalence based on Rome III criteria was 13.1% (1,309/10,000) (Table 1). The prevalence among women was 15.5% and that among men was 10.7%. Among the subjects who met Rome III criteria, 29% were categorized as having IBS-D, with this subtype being more common among males (male 47%, female 17%; Figure 3). Conversely, although 24% were classified as having IBS- C, the majority was female (male 9%, female 34%; Figure 3). Forty-seven percent of subjects were classified as having IBS-M (male 44%, female 49%). The prevalence of the IBS-D was highest among males in their 20s (7.2%), and that of IBS-C was highest among females in their 20s (7.6%) (Figure 3). The IBS prevalence based on Rome II criteria was 9.8%. Thus, revision to Rome III criteria increased this percentage by about 1.3 times. Incidentally, 7.1% of the subjects satisfied both Rome II criteria and Rome III criteria, 6.0% satisfied Rome III criteria only, 2.7% satisfied Rome II criteria only, and 84.2% satisfied neither of the two (Table 1). Discussion We conducted a large-scale, Internet-based epidemiological study investigating 10,000 general consumers across Japan according to Rome III criteria. As subjects were those registered on the Internet, one demerit was that doctors and other medical professionals were unable to directly assess them. Furthermore, generally speaking, some of the problems entailed by Internet surveys, compared to conventional interview surveys, are such as when respondents pretend to be someone they are not and when the selection of respondents is biased. For this study, we took some measures to prevent such problems; we asked the respondents their personal information (to prevent them from pretending to be someone they are not) while adopting a stratified random sampling method by gender and age (to avoid any biased selection of respondents). Consequently, as many as 10,000 consumers nationwide were enrolled into the study, with each age group equally consisting of 1,000 subjects, and IBS prevalence was considered accurate. Actually, IBS prevalence was nearly consistent between the present study and IBS epidemiological studies conducted in Japan. As of 2004, two years before this questionnaire was performed, Internet use by those aged 65 years or older was less than 50% (Ministry of Internal Affairs and Communications 2004), while use by those in their 20s to 40s exceeded 80%. Thus, Internet surveys are an appropriate means for collecting facts on IBS, a syndrome most frequently observed in younger generations. 144 Patient Preference and Adherence 2008:2

IBS prevalence in japan Q1 Have you had any of the following symptoms in the last 3 months? (Multiple responses) 1. Headache 2. Head feels heavy 3. Dizziness/Giddiness 4. Ringing ears 5. Violent sneezing 6. Swelling 7. Itchy skin/itchy body 8. Coughing 9. Heart flutter/palpitation 10. Nausea/Queasiness 11. Stomach ache 12. Flatulence 13. Loose bowels 14. Diarrhea 15. Constipation (including hard stools) 16. Blood in stools 17. Frequent toilet visits (urine) 18. Difficulty in urinating 19. ED/Erection problems 20. Loss of sex drive 21. Cold hands and feet 22. Easily tired/lethargy 23. Insomnia/Frequent waking at night 24. Feel depressed/lack of energy 25. Irritation 26. Inability to concentrate 27. Sleepy in the daytime 28. None of the above Questions to respondents who answered 13. Loose bowels, 14. Diarrhea, or 15. Constipation (including hard stools) in Q1. If you answered Loose bowels, Diarrhea or Constipation (including hard stools) in Q1. Q2 Which of the following most closely describes your symptoms ( Loose bowels, Diarrhea or Constipation (including hard stools) )? 1. Mostly Loose bowels/diarrhea 2. Both Loose bowels/diarrhea and Constipation, but Diarrhea is more frequent 3. Both Loose bowels/diarrhea and Constipation, but Constipation is more frequent 4. Mostly Constipation Q3 When you have these symptoms ( Loose bowels, Diarrhea or Constipation (including hard stools) ), do you also have one of Abdominal pain or Discomfort? 1. One of Abdominal pain or Discomfort 2. Neither Abdominal pain nor Discomfort Q4 How frequently do you have the symptom in question ( Loose bowels, Diarrhea or Constipation (including hard stools) )? Please answer each section. The symptom has appeared on three or more days per month in the last three months The symptom appears for a total ( 1) of 90 or more days in a year Yes No 1 2 1 2 The symptom is repeated for a month 1 2 or more ( 2) 1 Even if the symptom is not continuous. 2 Repeated means that the symptom appears intermittently. Q5 When did you first start to be concerned about the symptom in question ( Loose bowels, Diarrhea or Constipation (including hard stools)? 1. Within the last month 2. About 3 months ago 3. About 6 months ago 4. About a year ago 5. About 2 3 years ago 6. About 4 9 years ago 7. At least 10 years ago 8. Don t know/can t remember Q6 Do any of the following occur when you have the symptom in question ( Loose bowels, Diarrhea or Constipation (including hard stools) )? Yes No Symptom eases after defecating 1 2 Frequency of defecation changes 1 2 Shape (hardness) of stools changes 1 2 Q7 Do you currently suffer from any ulcer, cancer or other disease in your stomach or intestines? 1. Yes 2. No Figure 1 Questionnaire (n = 10,000). Patient Preference and Adherence 2008:2 145

Miwa General consumers (n = 10,000) Persons with abnormal bowel habits General consumers with symptoms such as bad stomach, diarrhea, and constipation (including hard stool) IBS* diagnostic items based on Rome III A. In the past three months, abdominal pain or discomfort has repeated for three or more days/month with two or more of the following changes: i) Symptoms improved with defecation ii) Excretion frequency changed with onset of symptoms iii) Stool form (hardness) changed with onset *Patients started to experience symptoms six or more months ago, and met all of the above criteria in the past three months Exclusive criteria (Red fl ag) Currently, no organic diseases such as ulcers and cancer are detected in the stomach or colon. IBS* diagnostic items based on Rome II B. In the past 12 months, abdominal pain or discomfort has developed (not necessarily continuously) for 90 or more days (12 weeks) with two or more of the following changes: i) Symptoms improved with defecation ii) Excretion frequency changed with onset of symptoms iii) Stool form (hardness) changed with onset Exclusive criteria (Red fl ag) Currently, no organic diseases such as ulcers and cancer are detected in the stomach or colon. IBS subjects based on Rome III criteria IBS subjects based on Rome II criteria Figure 2 Diagnostic items of irritable bowel syndrome. Abbreviations: IBS, irritable bowel syndrome. The results of this study revealed that the total IBS prevalence in Japan is approximately 13.1%. Also, IBS prevalence based on Rome II criteria is 9.8%. Meanwhile, only 2.7% of the subjects satisfy Rome II criteria and this suggests that the prevalence rate was increased by the symptom duration being shortened from 12 months to 6 months. Based on demographic data (as of November 1, 2005) from the Bureau of Statistics, Japanese Ministry of Internal Affairs and Communications (2006), about 12 million consumers are estimated to have IBS across the nation. Given that there are an estimated 16.2 million Japanese with actual and possible diabetes (Ministry of Health, Labour and Table 1 Number of subjects with IBS by IBS diagnostic criteria (%) Diagnostic criteria (n = 10,000) 95% confidence interval According to Rome III criteria 13.1% (1,309 persons) 12.4% 13.8% According to Rome II criteria 9.8% (976 persons) 9.2% 10.3% According to Rome II criteria and Rome III criteria 7.1% (706 persons) 6.6% 7.6% According to Rome III criteria only 6.0% (603 persons) 5.6% 6.5% According to Rome II criteria only 2.7% (270 persons) 2.4% 3.0% Neither Rome II criteria nor Rome III criteria 84.2% (8,421 persons) 83.5% 84.9% Abbreviations: IBS, irritable bowel syndrome. 146 Patient Preference and Adherence 2008:2

IBS prevalence in japan (%) 18 16 14 12 10 8 6 4 2 0 (%) 16 14 12 10 8 6 4 2 0 (%) 25 20 15 10 5 0 13.7 1.0 5.5 7.2 13.1 3.1 6.1 3.9 Total Male 20s 21.9 7.6 11.8 2.5 Female 20s 13.4 0.3 6.3 6.8 Male 30s 19.0 6.0 9.1 10.7 1.0 4.7 5.0 Male 10.3 0.9 4.6 4.8 Male 40s 14.9 4.5 7.0 3.9 3.4 8.9 0.5 4.1 4.3 Male 50s 11.4 4.1 5.6 15.5 5.3 7.5 2.7 Female 7.0 2.1 3.0 1.9 Male over 60 10.4 4.2 4.2 1.7 2.0 Female 30s Female 40s Female 50s Female over 60 Constipation Mixed Diarrhea Figure 3 Prevalence of IBS by subtype, gender, and age group according to Rome III criteria. Welfare 2003), the illness is called a national affliction of the Japanese. The results of our study confirmed once again that the prevalence of IBS is very high as compared to diabetic data in Japan. The prevalence of IBS among 5,000 males and 5,000 females was 10.7% and 15.5%, respectively. Analysis based on the stratification by age group revealed that, irrespective of gender, IBS was observed more frequently in younger populations. By subtype of the disease, IBS-D was more common among males and IBS-C among females. The former type of IBS is said to result in poorer QOL than the latter type (Kevin et al 2006). Given that there are more male patients with IBS-D in Japan, the impact on society is higher than in other countries. In the past, as IBS excluded transient bowel habit problems caused by acute diseases such as gastroenteritis, it had to be set with a prolonged symptom duration (Thompson et al 1999). In this study, Rome III criteria were used for diagnosis. On the new diagnostic criteria, the symptom duration of IBS has been reduced to 6 months. IBS prevalence according to Rome III criteria increased about 1.3 times compared with Rome II criteria. The results suggest that diagnosis based on Rome III in the future may identify more IBS patients, who would not be given such a diagnosis with the older diagnostic criteria. In conclusion, IBS prevalence based on Rome III criteria was 13.1%. On the other hand, IBS prevalence based on Rome II criteria was 9.8%. These results indicate an increase in the number of IBS patients due to the symptom duration being shortened to 6 months. References Chang L, Heitkemper MM. 2002. Gender differences in irritable syndrome. Gastroenterology, 123:1686 701. Drossman DA, Richter JE, Talley NJ, et al. 1994. Functional gastrointestinal disorders. Boston: Little, Brown and Co, pp. 1 174. Drossman DA, Whitehead WE, Camilleri M, et al. 1997. Irritable bowel Syndrome: A technical review for practice guideline development. Gastroenterology, 112:2120 37. Gralnek IM, Hays RD, Kilbourne A, et al. 2000. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology, 119:654 60. Kanazawa M, Endo Y, Whitehead WE, et al. 2004. Patients and nonconsulters with irritable bowel syndrome reporting a parental history of bowel problem have more impaired psychological distress. Dig Dis Sci, 49:1046 53. Kang JY. 2005. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. Aliment Pharmacol Ther, 21:663 76. Kevin C, Peggy H, Monica E, et al. 2006. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol, 101:124 32. Kumano H, Kaiya H, Yoshiuchi K, et al. 2004. Comorbidity of irritable bowel syndrome, panic disorder, and agoraphobia in Japanese representative sample. Am J Gastroenterol, 99:370 6. Longstreth GF, Thompson WG, Chey WD, et al. 2006. Functional bowel disorders. Gastroenterology, 130:1480 91. Manning AP, Thompson WG, Heaton KW, et al. 1978. Towards positive diagnosis of the irritable bowel syndrome. BMJ, ii:653 4. Ministry of Health, Labour and Welfare. 2003. Diabetes Survey FY2002 [online; in Japanese]. Accessed on December 10, 2007. URL: http:// www.mhlw.go.jp/shingi/2004/03/s0318-15.html. Ministry of Internal Affairs and Communications. 2004. Communications Use Survey. Ministry of Internal Affairs and Communications. 2006. Current Population Estimates as of November 1, 2005. Bureau of Statistics [online; in Japanese]. Accessed December 10, 2006. URL: http://www.stat. go.jp/data/jinsui/index.htm. Saito YA, Schoenfeld P, Locke GR. 2002. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol, 97:1910 15. Talley NJ. 1999. Irritable bowel syndrome: definition, diagnosis and epidemiology. Baillieres Best Pract Res Clin Gastroenterol, 13:371 84. Thompson WG, Creed F, Drossman DA, et al. 1992. Functional bowel disorders and chronic functional abdominal pain. Gastroenterol Int, 5:75 91. Thompson WG, Longstreth GF, Drossman DA, et al. 1999. Functional bowel disorders and functional abdominal pain. Gut, 45(Suppl II):II43 7. Patient Preference and Adherence 2008:2 147